Virus cocktail aims to make inoperable esophageal cancer removable
NCT ID NCT07061704
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether injecting a cancer-killing virus directly into tumors, combined with standard chemotherapy and an immunotherapy drug, can shrink advanced esophageal cancer enough to allow surgery. About 40 adults with unresectable locally advanced esophageal squamous cell carcinoma will receive the virus every 3 weeks along with intravenous chemo and immunotherapy. The goal is to see if this approach can turn inoperable tumors into operable ones and improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oncolytic virus (injected into tumors) plus chemotherapy and an immune checkpoint inhibitor
What this could lead to
If successful, this combination could shrink inoperable esophageal tumors enough to allow surgery, potentially improving survival and quality of life.
What could go wrong
This is an early-phase, single-arm trial with only 40 participants, so results may not apply broadly. The virus injection carries risks like infection or inflammation, and the combination may cause severe side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••